6505--Mycophenolate Mofetil RFP
ID: 36E79725R0010Type: Solicitation
Overview

Buyer

VETERANS AFFAIRS, DEPARTMENT OFVETERANS AFFAIRS, DEPARTMENT OFNAC PHARMACEUTICALS (36E797)HINES, IL, 60141, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/54d5b7d7f46f4d16977ec6d90c0e95d3/view
Timeline
    Description

    The Department of Veterans Affairs is seeking proposals for the procurement of Mycophenolate Mofetil capsules and tablets under Solicitation Number 36E79725R0010, aimed at establishing national pricing for these pharmaceutical products. The contract is intended to support various government health care facilities, including those under the Department of Defense and Indian Health Service, ensuring compliance with FDA standards and the Drug Supply Chain Security Act. Offerors are required to submit pricing for both the base year and four option years, with a deadline for submissions extended to March 4, 2025, at 2:30 PM CST, and must acknowledge receipt of this amendment to avoid rejection of their offers. Interested parties can contact Contract Specialist Amber Zavala at amber.zavala@va.gov for further information.

    Point(s) of Contact
    Amber ZavalaContract Specialist
    amber.zavala@va.gov
    Files
    Title
    Posted
    36E79725R0010_1.docx
    The Department of Veterans Affairs (VA) National Acquisition Center is preparing to release a Request for Proposal (RFP) numbered 36E79725R0010 for the procurement of Mycophenolate Mofetil tablets and capsules. This unrestricted procurement will serve several federal entities, including the Department of Defense and the Bureau of Prisons. The VA plans to award a single contract to a reliable supplier for a one-year term, with the option to extend for four additional years. The contract requires compliance with specific packaging standards, such as child-resistant closures for smaller bottles. The estimated annual requirements for various Mycophenolate Mofetil products have been detailed, specifying quantities for differing sizes of capsules and tablets. The solicitation will be electronically issued on or around February 14, 2025, with offers accepted until February 28, 2025. Interested parties must check the designated URL for updates and should direct questions to the contact person, Amber Zavala. This procurement process underscores the VA's commitment to ensuring a stable supply of essential medications for veterans and associated federal programs.
    36E79725R0010.docx
    This document is a solicitation for contracts related to the procurement of pharmaceutical products, specifically Mycophenolate Mofetil capsules and tablets, by the Department of Veterans Affairs (VA) under its Pharmaceutical Prime Vendor (PPV) Program. The contract aims to establish national prices for the specified drugs to meet the requirements of various government participants, including DoD and IHS facilities. Offerors must submit pricing for both the base year and four option years for all line items included. The social and product specifications, such as 11-digit NDC numbers, are detailed, with contractors required to maintain compliance with FDA standards and provide quarterly sales reports, including a 0.5% Cost Recovery Fee embedded in prices. The contract has an implementation period followed by an ordering period where pharmaceutical vendors must supply products effectively to various federal health care facilities. The document outlines compliance requirements, delivery expectations, and guidelines on backorders and recalls, stressing the importance of maintaining uninterrupted product availability. Additionally, it emphasizes adherence to the Drug Supply Chain Security Act, ensuring safe and regulated distribution of pharmaceutical goods. The government's goal is to ensure consistent product access while optimizing cost efficiencies through competitive pricing.
    36E79725R0010 0001.docx
    This document is an amendment related to Solicitation Number 36E79725R0010, issued by the Department of Veterans Affairs' National Acquisition Center. The main purpose of this amendment is to extend the deadline for receiving offers until March 4, 2025, at 2:30 PM CST. The amendment reiterates the importance of acknowledging receipt of this change, outlining various methods for offerors to confirm acceptance. It emphasizes that failure to acknowledge by the specified deadline may result in offer rejection. While the submission deadline is modified, all other terms and conditions of the solicitation remain unchanged. This document serves as a formal notice to potential bidders regarding the updated timeline, ensuring they are informed and able to comply with submission requirements.
    Lifecycle
    Title
    Type
    6505--Mycophenolate Mofetil RFP
    Currently viewing
    Solicitation
    6505--Mycophenolate Mofetil RFP
    Presolicitation
    Similar Opportunities
    6505--Rituximab and Biosimilars
    Buyer not available
    The Department of Veterans Affairs is soliciting proposals for the procurement of Rituximab 10mg/ml and its biosimilars, aimed at establishing a reliable pharmaceutical supply source for government healthcare facilities. Bidders are required to provide unique National Drug Code (NDC) numbers for their products and include a 0.5% Cost Recovery Fee in their pricing, with the contract covering a base year and four optional subsequent years. This procurement is critical for ensuring consistent product availability and pricing based on estimated annual usage, while adhering to FDA regulations and the Drug Supply Chain Security Act (DSCSA) for safety and traceability. Interested suppliers must submit their proposals by March 11, 2025, at 2:30 PM CT, and can contact Contract Specialist Deborah S Fassl at Deborah.Fassl@va.gov for further information.
    6505--Hydroxychloroquine SO4 Tablets
    Buyer not available
    The Department of Veterans Affairs (VA) is issuing a Request for Proposal (RFP) for the procurement of Hydroxychloroquine SO4 Tablets, aimed at ensuring a continuous supply for various federal entities, including the Department of Defense and the Bureau of Prisons. The contract will cover an estimated annual requirement of 163,395 bottles of 100-count and 25,853 bottles of 500-count Hydroxychloroquine tablets, with a contract period of one year and four optional one-year extensions. This procurement is critical for maintaining essential medications within veteran and federal healthcare programs. Interested parties should monitor SAM.gov for updates and direct inquiries to the contracting officer, Chris Carthron, at Christopher.Carthron@va.gov or (708) 786-4980, with submissions due by March 26, 2025.
    6509--Solifenacin Tabletes (VA-25-00037090)
    Buyer not available
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Solifenacin Tablets, designated as RFP 36E79725R0020. This procurement aims to establish a reliable supply of Solifenacin for the VA, Department of Defense (DoD), and other federal health agencies, with the contract expected to last one year and include four optional renewal periods. Solifenacin is a critical medication used in the treatment of overactive bladder, highlighting the VA's commitment to ensuring access to essential pharmaceuticals for veterans and associated healthcare providers. Interested vendors should monitor SAM.gov for the RFP release, anticipated around March 14, 2025, with proposals due by March 28, 2025; for further inquiries, they may contact Contract Specialist Kenneth Lay at Kenneth.Lay@va.gov or by phone at 708-786-4879.
    Dimethyl Fumarate DR Presolicitation
    Buyer not available
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
    6505--Insulin (VA-25-00026482)
    Buyer not available
    The Department of Veterans Affairs is soliciting proposals for the procurement of insulin and related pharmaceutical products under the solicitation titled "6505--Insulin (VA-25-00026482)." This procurement aims to establish a reliable supply source for the Department of Veterans Affairs and the Department of Defense, requiring offerors to submit competitive pricing for a base year plus four option years, including a 0.5% Cost Recovery Fee. Compliance with the Drug Supply Chain Security Act (DSCSA), adherence to current good manufacturing practices (cGMP), and provision of unique National Drug Codes (NDC) for the offered products are critical requirements. Interested parties should direct inquiries to Contract Specialist Billy Fong at Billy.Fong@va.gov, with proposals due by the specified deadline outlined in the solicitation document.
    6505--Diclofenac Sodium (NA) 1% Gel
    Buyer not available
    The Department of Veterans Affairs (VA) is soliciting proposals for the supply of Diclofenac Sodium (NA) 1% Gel, intended for use in its pharmaceutical programs as well as those of the Department of Defense (DoD). Contractors are required to provide pricing for a base year along with four one-year option years, ensuring compliance with federal drug regulations and the Drug Supply Chain Security Act (DSCSA). This procurement is critical for maintaining a reliable supply of pharmaceutical products that meet stringent manufacturing standards and public health requirements. Interested parties must submit their offers by March 4, 2025, at 2:30 PM Central Time, and can contact Contract Specialist Ray Roldan at Raymond.Roldan@va.gov for further information.
    6505--762_Pharmaceuticals_VA CMOP Tucson_36C77025Q0168 762-25-2-040-1176 -Tucson CMOP HYDROXYCHLOROQUINE SULFATE
    Buyer not available
    The Department of Veterans Affairs is seeking proposals for the procurement of Hydroxychloroquine Sulfate 200mg tablets, with a total quantity of 5,412 to be delivered to the CMOP facility in Tucson, Arizona. This presolicitation, identified by solicitation number 36C77025Q0168, is set aside for small businesses and requires compliance with the Buy American statute, necessitating quotes for both foreign and domestic products. Hydroxychloroquine is a critical pharmaceutical used in the treatment of various conditions, making this procurement essential for the healthcare services provided to veterans. Interested vendors must submit their proposals by March 5, 2025, at 09:00 Central Time, and can direct inquiries to Contract Specialist Michael W. McAlhaney via email at Michael.McAlhaney@va.gov or by phone at (913) 684-0134.
    6505--770-25-1-801-0131 -National CMOP DORZOLAMIDE/TIMOLOL -(VA-25-00027395)
    Buyer not available
    The Department of Veterans Affairs is soliciting bids for the procurement of Dorzolamide 22.3/Timolol 6.8mg/ml ophthalmic solution as part of its National Consolidated Mail Outpatient Pharmacy (CMOP) program. This solicitation requires vendors to submit a signed cover page, pricing schedule, and documentation such as a valid state distributor license and a Trade Agreements Act certificate, ensuring compliance with regulatory standards for pharmaceutical products. The procurement is critical for providing quality healthcare services to veterans, emphasizing the importance of product safety, therapeutic equivalence, and adherence to delivery schedules. Interested vendors must submit their quotes by March 5, 2025, at 3:00 PM Central Time, and can contact Contract Specialist Kelley Cunningham at kelley.cunningham@va.gov for further inquiries.
    760-25-1-050-0154 -Leavenworth CMOP THYROID TABLETS -(VA-25-00022614)
    Buyer not available
    The Department of Veterans Affairs is soliciting proposals for the procurement of Armour Thyroid tablets for the Leavenworth Consolidated Mail Outpatient Pharmacy (CMOP) under solicitation number 36C77025Q0079. This Request for Quotation (RFQ) emphasizes the need for specific brand-name pharmaceuticals, with a focus on compliance with federal regulations, including the Drug Supply Chain Security Act and the Buy American Act. The procurement process aims to ensure a reliable supply of essential medications for veterans, with a firm-fixed-price contract expected to be awarded based on fair market evaluations. Interested vendors must submit their quotes by December 27, 2024, at 4:00 PM CST, and can direct inquiries to Jennifer L. Knight at jennifer.knight@va.gov or by phone at 913-684-0162.
    6505--Bevacizumab Injection
    Buyer not available
    The Department of Veterans Affairs is soliciting proposals for the procurement of Bevacizumab injections, a critical pharmaceutical product used in various healthcare settings for veterans. Vendors are required to meet specific criteria, including providing unique National Drug Codes (NDC) and adhering to the Drug Supply Chain Security Act regulations, as the contract aims to ensure a reliable supply of this medication across government health care facilities. The selected contractor will be responsible for multiple line items of different Bevacizumab formulations, maintaining compliance with FDA manufacturing practices, and submitting quarterly sales reports, including cost recovery fees. Interested vendors should contact Contract Specialist Matthew S. Poulin at Matthew.Poulin@va.gov for further details, with submissions due by the specified deadlines outlined in the solicitation document.